Serum and Nasal Lavage Fluid Eosinophil‐Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes
Authors:
- Saliha Selin Özuygur ErmisSESaliha Selin Özuygur Ermis
- Carina MalmhällCMCarina Malmhäll
- Magnus P. BorresMBMagnus P. Borres
- Robert MovérareRMRobert Movérare
- Daniil LisikDLDaniil Lisik
- Reshed AbohalakaRAReshed Abohalaka
- Selin ErcanSESelin Ercan
- Rani BasnaRBRani Basna
- Roxana MinchevaRMRoxana Mincheva
- Göran WennergrenGWGöran Wennergren
- Jan LötvallJLJan Lötvall
Open Access
- 23 June 2026
- journal article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (6) , e70183
Abstract
Background: As a surrogate for eosinophilic activation, eosinophil‐derived neurotoxin (EDN) is a potential clinical biomarker. However, EDN levels and discriminatory ability in different asthma phenotypes are unknown. We quantified serum and nasal lavage fluid (NLF) EDN levels and assessed the potential to differentiate clinically defined asthma phenotypes in an adult‐representative sample. Methods: A total of 1499 serum and 386 NLF samples from individuals with current asthma obtained from the West Sweden Asthma Study were analyzed for EDN. Eosinophilic asthma was defined as blood eosinophil count of ≥ 300 cells/mm 3 , T2‐high asthma was defined as blood eosinophil count of ≥ 300 cells/mm 3 or fractional exhaled nitric oxide (FeNO) levels of ≥ 25 ppb. Other asthma phenotypes were defined based on presence of atopy, chronic rhinosinusitis (CRS), nasal polyposis, and obesity. Results: Subjects with eosinophilic asthma had higher serum and NLF EDN levels than those with non‐eosinophilic asthma. In ROC analyses, serum EDN provided excellent discrimination between eosinophilic and non‐eosinophilic asthma (area under curve [AUC] = 0.84, 95% CI = 0.82–0.86); the corresponding AUC for NLF EDN was 0.67 (95% CI = 0.62–0.73). Serum and NLF EDN were higher in atopic asthma, T2‐high asthma, and asthma with nasal polyposis compared to their counterparts, but not in asthma with CRS. The highest absolute values of serum and NLF EDN were observed in the high eosinophil + FeNO group, followed by the high‐eosinophil‐only and high‐FeNO‐only groups. Conclusion: Both serum and NLF EDN were higher in those with eosinophilic compared to non‐eosinophilic asthma. However, only serum EDN appears to distinguish eosinophilic asthma in ROC analyses.Keywords
Funding Information
- Vetenskapsrådet (2019–00247)
- Astma- och Allergiförbundet (F2021‐0041)
This publication has 43 references indexed in Scilit:
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN studyAllergy, 2011
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Large scale questionnaire survey on respiratory health in Sweden: Effects of late- and non-responseRespiratory Medicine, 2009
- Serum Eosinophil-Derived Neurotoxin (EDN) in Diagnosis and Evaluation of Severity and Bronchial Hyperresponsiveness in Childhood AsthmaLung, 2007
- Asthma: defining of the persistent adult phenotypesThe Lancet, 2006
- Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitisJournal of Allergy and Clinical Immunology, 2003
- Eosinophil cationic protein and eosinophil protein X in the nasal lavage of children during the first 4 weeks of lifeAllergy, 2000
- Quantification of Cytokines and Inflammatory Mediators in Samples of Nasopharyngeal Secretions with Unknown DilutionPediatric Research, 1999
- Asthma in children less than 5 years of age: eosinophils and serum levels of the eosinophil proteins ECP and EPX in relation to atopy and symptomsClinical & Experimental Allergy, 1994